CoChat

Llama immunization with full-length VAR2CSA generates cross-reactive and inhibitory single-domain antibodies against the DBL1X domain

Open access
Nunes-Silva, Sofia, Gangnard, Stéphane, Vidal, Marta, Vuchelen, Anneleen, Dechavanne, Sebastien, Chan, Sherwin, Pardon, Els, Steyaert, Jan, Ramboarina, Stephanie, Chêne, Arnaud, Gamain, Benoît · 2014 · Scientific Reports

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

VAR2CSA stands today as the leading vaccine candidate aiming to protect future pregnant women living in malaria endemic areas against the severe clinical outcomes of pregnancy associated malaria (PAM). The rational design of an efficient VAR2CSA-based vaccine relies on a profound understanding of the molecular interactions associated with P. falciparum infected erythrocyte sequestration in the placenta. Following immunization of a llama with the full-length VAR2CSA recombinant protein, we have expressed and characterized a panel of 19 nanobodies able to recognize the recombinant VAR2CSA as well as the surface of erythrocytes infected with parasites originating from different parts of the world. Domain mapping revealed that a large majority of nanobodies targeted DBL1X whereas a few of them were directed towards DBL4ε, DBL5ε and DBL6ε. One nanobody targeting the DBL1X was able to recognize the native VAR2CSA protein of the three parasite lines tested. Furthermore, four nanobodies targeting DBL1X reproducibly inhibited CSA adhesion of erythrocytes infected with the homologous NF54-CSA parasite strain, providing evidences that DBL1X domain is part or close to the CSA binding site. These nanobodies could serve as useful tools to identify conserved epitopes shared between different variants and to characterize the interactions between VAR2CSA and CSA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep07373

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Recognition of full-length VAR2CSA recombinant protein by the different nanobodies. ELISA plates were coated with 1 µg/ml of full-length recombinant VAR2CSA protein (3D7-DBL1X-6ε) and incubated with the 29 nanobodies (0.3 µg/ml). Nanobody binding was detected with an HRP-conjugated goat anti-llama IgG and revealed with TMB substrate. Optical density was measured at 655nm.
Figure 1 Recognition of full-length VAR2CSA recombinant protein by the different nanobodies. ELISA plates were coated with 1 µg/ml of full-length recombinant VAR2CSA protein (3D7-DBL1X-6ε) and incubated with the 29 nanobodies (0.3 µg/ml). Nanobody binding was detected with an HRP-conjugated goat anti-llama IgG and revealed with TMB substrate. Optical density was measured at 655nm.CC BY-NC-ND · PubMed Central
Figure 2 Mapping of the VAR2CSA domains targeted by the nanobodies. ELISA plates were coated at 1 µg/ml with (a) recombinant VAR2CSA multi-domains 3D7-DBL1X-6ε, 3D7-DBL1X-3X, 3D7-DBL4ε-6ε and FCR3-DBL3X-4ε, (b) recombinant VAR2CSA single-domains 3D7-DBL1X, 3D7-DBL2X, FCR3-DBL3X and (c) recombinant VAR2CSA single-domains 3D7-DBL5ε, 3D7-DBL6ε and FCR3-DBL6ε, and incubated with the 29 nanobodies (0.3 µg/ml). Nanobody binding was detected with an HRP-conjugated goat anti-llama IgG and revealed with TMB substrate. Optical density was measured at 655nm. (d) Representation of the different nanobody specificities on VAR2CSA.
Figure 2 Mapping of the VAR2CSA domains targeted by the nanobodies. ELISA plates were coated at 1 µg/ml with (a) recombinant VAR2CSA multi-domains 3D7-DBL1X-6ε, 3D7-DBL1X-3X, 3D7-DBL4ε-6ε and FCR3-DBL3X-4ε, (b) recombinant VAR2CSA single-domains 3D7-DBL1X, 3D7-DBL2X, FCR3-DBL3X and (c) recombinant VAR2CSA single-domains 3D7-DBL5ε, 3D7-DBL6ε and FCR3-DBL6ε, and incubated with the 29 nanobodies (0.3 µg/ml). Nanobody binding was detected with an HRP-conjugated goat anti-llama IgG and revealed with TMB substrate. Optical density was measured at 655nm. (d) Representation of the different nanobody specificities on VAR2CSA.CC BY-NC-ND · PubMed Central
Figure 3 (a) Flow chart summarizing the nanobody selection and screening results. (b) Sequence alignment of the 19 nanobody amino-acid sequences. Complementarity determining regions (CDRs) are indicated according the international ImMunoGeneTics information system® (IMGT).
Figure 3 (a) Flow chart summarizing the nanobody selection and screening results. (b) Sequence alignment of the 19 nanobody amino-acid sequences. Complementarity determining regions (CDRs) are indicated according the international ImMunoGeneTics information system® (IMGT).CC BY-NC-ND · PubMed Central
Figure 4 Nanobodies recognize mostly conformational epitopes. Reduced and non-reduced recombinant protein VAR2CSA (3D7-DBL1X-6ε) was transferred onto membranes by Western blotting and probed with the nanobodies (0.5 µg/ml). Nanobody binding was detected with an HRP-conjugated goat anti-llama IgG. (a) Western blot with anti-DBL1X nanobodies. (b) Western blot with anti-DBL4ε nanobody. (c) Western blot with anti-DBL5ε nanobodies. (d) Western blot with anti-DBL6ε nanobodies.
Figure 4 Nanobodies recognize mostly conformational epitopes. Reduced and non-reduced recombinant protein VAR2CSA (3D7-DBL1X-6ε) was transferred onto membranes by Western blotting and probed with the nanobodies (0.5 µg/ml). Nanobody binding was detected with an HRP-conjugated goat anti-llama IgG. (a) Western blot with anti-DBL1X nanobodies. (b) Western blot with anti-DBL4ε nanobody. (c) Western blot with anti-DBL5ε nanobodies. (d) Western blot with anti-DBL6ε nanobodies.CC BY-NC-ND · PubMed Central
Figure 5 RaPID plot of the nanobodies. kon and koff values for each VHH to the VAR2CSA antigen are indicated as dots on the 2-dimensional plot next to labels denoting the VHH clone.
Figure 5 RaPID plot of the nanobodies. kon and koff values for each VHH to the VAR2CSA antigen are indicated as dots on the 2-dimensional plot next to labels denoting the VHH clone.CC BY-NC-ND · PubMed Central
Figure 6 Nanobodies raised against VAR2CSA recognize placental-type infected erythrocytes. Nanobody recognition by flow cytometry of native VAR2CSA expressed at the surface of infected erythrocytes with parasite strains NF54 (homologous parasite strain), FCR3 and 7G8 selected for CSA-binding and FCR3 selected for CD36-binding. Nanobody binding was detected with a mouse anti-His IgG and a PE-conjugated goat anti-mouse IgG. The Geometric Mean PE ratio was calculated using the negative control (without nanobody). The different DBLs targeted by the nanobodies are depicted in the figure. Error bars represent the standard deviation of data obtained from three independent experiments (NF54-CSA) and two independent experiments (7G8-CSA).
Figure 6 Nanobodies raised against VAR2CSA recognize placental-type infected erythrocytes. Nanobody recognition by flow cytometry of native VAR2CSA expressed at the surface of infected erythrocytes with parasite strains NF54 (homologous parasite strain), FCR3 and 7G8 selected for CSA-binding and FCR3 selected for CD36-binding. Nanobody binding was detected with a mouse anti-His IgG and a PE-conjugated goat anti-mouse IgG. The Geometric Mean PE ratio was calculated using the negative control (without nanobody). The different DBLs targeted by the nanobodies are depicted in the figure. Error bars represent the standard deviation of data obtained from three independent experiments (NF54-CSA) and two independent experiments (7G8-CSA).CC BY-NC-ND · PubMed Central
Figure 7 Four nanobodies against DBL1X reproducibly inhibit CSA adhesion of the homologous NF54-CSA line. Adhesion assays on CSA-coated plastic spots were performed using purified erythrocytes infected with the NF54 parasite line and selected for the CSA-binding phenotype. Nineteen different nanobodies were tested for their ability to inhibit the IEs binding to CSA. The percentage of binding for a given condition was calculated using the number of adherent cells obtained with IEs pre-incubated with PBS alone as a reference (100% binding). The different DBLs targeted by the nanobodies are depicted in the figure. Error bars represent the standard deviation of three independent experiments.
Figure 7 Four nanobodies against DBL1X reproducibly inhibit CSA adhesion of the homologous NF54-CSA line. Adhesion assays on CSA-coated plastic spots were performed using purified erythrocytes infected with the NF54 parasite line and selected for the CSA-binding phenotype. Nineteen different nanobodies were tested for their ability to inhibit the IEs binding to CSA. The percentage of binding for a given condition was calculated using the number of adherent cells obtained with IEs pre-incubated with PBS alone as a reference (100% binding). The different DBLs targeted by the nanobodies are depicted in the figure. Error bars represent the standard deviation of three independent experiments.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

Metadata

Authors
Nunes-Silva, S., Gangnard, S., Vidal, M., Vuchelen, A., Dechavanne, S., Chan, S., Pardon, E., Steyaert, J., Ramboarina, S., Chêne, A., & Gamain, B.
Affiliations
  • Inserm (FR)
  • Vrije Universiteit Brussel (BE)
  • Karolinska Institutet (SE)
Corresponding author
Gamain, Benoît
Venue
Scientific Reports
Published
2014-12-09
Volume
4
Issue
1
Pages
7373-7373
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2169113984
Cited by
15
References
48
Citations by year
2026: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 1 · 2016: 6 · 2015: 3
FWCI
2.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
  • Agence Nationale de la Recherche (ANR 11 IDEX 0005-02, ANR-11-LABX-0051, IDEX-0005, ANR-11-IDEX, ANR-11-IDEX-0005)
  • Belgian Federal Science Policy Office
  • Fonds Wetenschappelijk Onderzoek
  • Vlaamse regering
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
Keywords
VAR2CSA, nanobodies, placental malaria, malaria in pregnancy, Plasmodium falciparum, erythrocyte sequestration, vaccine candidate, epitope mapping, cross-reactivity, inhibitory antibodies
MeSH terms
Amino Acid Sequence, Animals, Epitopes, Antigens, Protozoan, Camelids, New World, Cross Reactions, Erythrocytes, Female, Humans, Immunization, Kinetics, Molecular Sequence Data, Placenta, Pregnancy, Protein Binding, Protein Conformation, Recombinant Proteins, Sequence Alignment, Epitope Mapping, Protein Interaction Domains and Motifs, Single-Domain Antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.